DANVILLE, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Palo Alto Health Sciences (PAHS), maker of the Freespira Breathing System®, is excited to welcome Dr. Robert Cuyler as Chief Clinical Officer and Mr. Christopher Jaquis as Vice President of Business Development. Dr. Cuyler and Mr. Jaquis join PAHS’ seasoned management team in bringing extensive experience in the behavioral health industry as PAHS expands partnerships with Payers and Health Systems to increase access to Freespira®.
“Palo Alto Health Sciences is dedicated to solving significant behavioral health conditions with evidence-based, non-invasive, drug-free solutions,” said Debra Reisenthel, CEO of Palo Alto Health Sciences, Inc. “Robert joining us now as we raise additional funding for expansion is another example of our commitment to clinical excellence and achieving great patient outcomes.”
Says Dr. Cuyler: “I have seen first-hand in my clinic how Freespira changes the lives of patients suffering from Panic Disorder and panic attacks. This technology has been rigorously tested and proven in clinical research and commercial practice, and I look forward to working with clinicians to offer the Freespira treatment to their patients.” Dr. Cuyler brings over 30 years of clinical and business development experience in the mental health arena. He previously was the Interim CEO of JSA Tele-psychiatry and Senior Vice President of Diamond Healthcare. Dr. Cuyler has over a decade of experience designing and implementing telemedicine and innovative technology programs throughout the United States. He received his Ph.D. in Clinical Psychology at Louisiana State University and completed a Post-Doctoral Fellowship in Psychology from the Menninger Foundation (Topeka, KS). While serving as CCO, he will continue to provide psychological services to clients in his Houston, TX practice on a limited basis.
“We are also thrilled to have Chris Jaquis accept the newly created VP of Business Development role,” shared Reisenthel. “Chris will greatly increase our ability to expand Freespira’s footprint with Health Systems and Payers to make it more broadly available to people suffering from panic.” Mr. Jaquis is a strategic growth expert with over 20 years of experience partnering with Payers and providers within the behavioral healthcare industry. He most recently served as the VP of Development at Townsend Addiction Treatment Centers (Lafayette, LA) where he grew in-network Payer relationships, which played a significant role in Townsend’s acquisition by American Addiction Centers. Before joining Townsend, Chris served as Strategic Accounts Director for Breakthrough Behavioral, a leader in tele-behavioral health delivery. Chris was responsible for execution of the company's sales strategy; Breakthrough’s success led to acquisition by MDLive in November of 2014. At CRC Health Inc., Chris held various senior leadership positions over 14 years. CRC became the largest for-profit Drug and Alcohol Treatment System in the U.S. “Freespira represents a rapid, cost-effective, clinically proven solution that has already garnered attention from the behavioral health community. I am thrilled to be working with the PAHS team to translate this interest into wider availability through major Health Systems and Payers,” said Mr. Jaquis.
Freespira. Cleared by FDA in 2013, Freespira is a non-invasive, drug-free, 4-week at home treatment for Panic Disorder and symptoms of panic. Completed under the supervision of a licensed healthcare provider, Freespira is clinically proven to reduce or eliminate the symptoms of Panic Disorder, the mental health condition in which debilitating anxiety and panic attacks result in avoidance behaviors. Panic symptoms include sweating, trembling, shortness of breath, chest discomfort, dizziness or nausea. Although people with panic disorder are typically unaware of their breathing patterns, many breathe differently all of the time, not just when they are having a panic attack. Freespira directly addresses this key physiological component of panic: “chronic hyperventilation.” Freespira trains the patient to stabilize their respiration rate and normalize their exhaled carbon dioxide (EtCO2) level and, over the course of treatment, this results in changes in the body’s chemistry, eliminating or reducing the symptoms of panic, including panic attacks. In a recent Freespira clinical trial, 98% of patients demonstrated reduction in their panic disorder severity scores (PDSS) and 62% were free from panic attacks after the four-week Freespira treatment. In prior clinical trials, 96% of patients reported symptom reduction and 68% of patients remained panic-attack free at 12 months post-treatment.
About Palo Alto Health Sciences, Inc.
Palo Alto Health Sciences, Inc. is a privately held Silicon Valley medical device company at the forefront of revolutionizing behavioral healthcare with evidence-based, non-invasive, drug-free solutions. Their first product, Freespira, is an FDA-cleared treatment for individuals suffering from Panic Disorder and symptoms of panic, including panic attacks. In the United States, over 6.7 million adults annually suffer from Panic Disorder; panic attacks affect a total of 27 million adults in the U.S. every year and are a common component of other anxiety disorders. Freespira is commercially available throughout the U.S. and therapists are successfully treating patients with outstanding results, even in the most severe cases.
To learn more, visit http://www.freespira.com or contact email@example.com.
Last updated on: 19/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.